Gene expression analysis of the ovarian cancer cell line A2780 after dose escalation and the development of acquired resistance to oxaliplatin and cisplatin revealed a 62-fold increase in COL6A3 transcript levels compared with therapy-sensitive clones, supporting the original reports [62]. This evidence concerns the gene COL6A3 and ovarian cancer.